Recent Analysts’ Ratings Updates for Orchestra BioMed (OBIO)

A number of research firms have changed their ratings and price targets for Orchestra BioMed (NASDAQ: OBIO):

• 5/19/2026 – Orchestra BioMed had its price target lowered by B. Riley Financial, Inc. from $12.00 to $10.00. They now have a “buy” rating on the stock.
• 5/16/2026 – Orchestra BioMed was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/14/2026 – Orchestra BioMed had its “buy” rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
• 5/13/2026 – Orchestra BioMed had its price target raised by Barclays PLC from $12.00 to $13.00. They now have an “overweight” rating on the stock.
• 4/21/2026 – Orchestra BioMed was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 4/2/2026 – Orchestra BioMed had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Activity at Orchestra BioMed

In related news, Director Jason Aryeh purchased 8,971 shares of the stock in a transaction on Friday, May 15th. The shares were purchased at an average cost of $3.90 per share, for a total transaction of $34,986.90. Following the completion of the transaction, the director directly owned 117,453 shares of the company’s stock, valued at approximately $458,066.70. The trade was a 8.27% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David P. Hochman purchased 10,000 shares of the stock in a transaction on Friday, March 13th. The stock was bought at an average price of $4.29 per share, for a total transaction of $42,900.00. Following the completion of the transaction, the insider directly owned 1,086,467 shares of the company’s stock, valued at approximately $4,660,943.43. This trade represents a 0.93% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 44,636 shares of company stock worth $181,831. 7.50% of the stock is owned by corporate insiders.

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical?stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high?unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early? and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.